TD Asset Management
CADX

TD Asset Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

TD Asset Management’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-113,600
Closed -$1.03M – 1351
2013
Q4 		$1.03M Sell
113,600
-29,300
-21% -$212K ﹤0.01% 881
2013
Q3 		$902K Buy
142,900
+10,100
+8% +$64.2K ﹤0.01% 884
2013
Q2 		$906K Buy
+132,800
New +$925K ﹤0.01% 852

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TD Asset Management's CADX Position: Q1 2014 in Review

TD Asset Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 113,600 shares — an estimated $1.03M sold.

TD Asset Management first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.03M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • TD Asset Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • TD Asset Management sold 113,600 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.03M.
  • TD Asset Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • TD Asset Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.03M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on TD Asset Management's 13F filing for Q1 2014, filed 9 May 2014.